Introduction {#Sec1}
============

The pathogenesis of gout is thought to require progression through three checkpoints: hyperuricaemia (HU), deposition of monosodium urate (MSU) crystals into articular and peri-articular structures, and an inflammatory response to these crystals \[[@CR1]\]. Genome-wide association studies (GWAS) have emphasised the contribution to urate control of genetic variation in renal and gut urate transporters, including *SLC2A9* and *ABCG2* \[[@CR2], [@CR3]\]. When combined, variants in these two genes explain 3--4% of variance in urate levels and have strong effects on the risk of gout \[[@CR4], [@CR5]\]. However, understanding of pathways regulating MSU crystal deposition and the inflammatory response to deposited crystals in gout remains important because fewer than a quarter of people with HU develop gout \[[@CR6]\]. Production of the inflammatory cytokine interleukin-1β (IL-1β) is central to the inflammatory response to MSU crystals \[[@CR7], [@CR8]\]. The pathway that produces IL-1β involves activation of the NLRP3 inflammasome, resulting in cleavage of pro-IL-1β to mature IL-1β by caspase-1. There is little knowledge, however, about the genetic variants that promote the formation of MSU crystals and initiate the innate immune response in the presence of HU \[[@CR9]\], although variants in the toll-like receptor 4 and components of the NLRP3 inflammasome have been associated with increased risk of gout \[[@CR10]--[@CR12]\].

The *ABCG2* gene was first associated with serum urate levels and gout by Dehghan et al. \[[@CR13]\]. The encoded protein (also known as breast cancer resistance protein) functions as a urate and oxypurinol transporter in the kidney and gut \[[@CR14]\]. The lysine (T) allele of the Q141K (*rs2231142*) single nucleotide polymorphism (SNP) is associated with HU and increased risk of gout (reviewed in \[[@CR14]\]). This variant decreases gut excretion of urate, contributing to a subtype of HU termed extra-renal under-excretion of urate \[[@CR15], [@CR16]\]. The 141K allele is also associated with a poor response to the principal urate-lowering therapy allopurinol (xanthine oxidase inhibitor) in people with gout \[[@CR17]--[@CR19]\]. Wen et al. \[[@CR17]\] reported a second genetically independent variant, *rs10011796*, associated with poor allopurinol response, although this association could not be replicated in a well-phenotyped, allopurinol-compliant sample set \[[@CR19]\]. SNP *rs10011796* strongly associated with urate in Europeans (*β* = 0.089 mg/dL, *P* = 2.4 × 10^− 51^), albeit with a weaker effect than *rs2231142* (*β* = 0.221 mg/dL, *P* = 4.4 × 10^− 116^) \[[@CR4]\].

The 141K variant creates instability in the protein's nucleotide-binding domain, reducing expression of *ABCG2* due to a processing defect and impaired trafficking to the cell membrane \[[@CR20]\]. This causes a 50% reduction of ABCG2-mediated uric acid excretion \[[@CR21]\]. Dysfunction can be rescued by low temperature \[[@CR22]\], and administration of small ligands, such as histone deacetylase inhibitors and colchicine, an anti-inflammatory drug used on the treatment of gout flares by disrupting neutrophil microtubule functioning \[[@CR20], [@CR23]\]. The defective protein is retained in aggresomes, a cellular pathway activated when proteasome activity is exceeded, and is subsequently degraded by the autophagy pathway \[[@CR23], [@CR24]\]. Deficiency in ABCG2 generates dysfunctional mitochondria \[[@CR25]\] and reduced copy number of mitochondrial DNA associates with increased risk of gout in NZ Polynesian \[[@CR26]\].

The observation that colchicine is able to rescue the 141K trafficking defect \[[@CR23]\], the proposal that autophagy machinery and the inflammasome interact in the innate immune response \[[@CR27]\], and evidence for association of *ABCG2 rs2231142* with gout in the presence of HU in East Asian populations \[[@CR28]--[@CR30]\], suggests that ABCG2 may be important in gout beyond its established role in elevating urate levels. This hypothesis is further supported by the observation that the effect size of *ABCG2* on urate in Europeans and Japanese is 58% and 73% that of *SLC2A9*, the most influential urate locus \[[@CR4], [@CR31]\], respectively, yet the effect size of *ABCG2* on gout is consistently larger than that of *SLC2A9* \[[@CR4], [@CR5], [@CR32]\]. Therefore, we tested the hypothesis in European and Aotearoa New Zealand Polynesian (NZ Māori and Pacific Island peoples) that *ABCG2* has a role in the progression of HU to gout using a genetic epidemiological approach by testing for association of *ABCG2 rs2231142* and *rs10011796* with gout in the presence of HU.

Participants and methods {#Sec2}
========================

Participants {#Sec3}
------------

The European sample set comprised 1699 participants with gout and 14,350 controls (2422 asymptomatic HU, and 11,928 NU). The NZ Polynesian sample set (individuals of NZ and Cook Island Māori, Samoan, Tongan, Niuean and Tokelauan ancestry) comprised 912 participants with gout, and 696 controls (202 HU and 494 NU) (Additional file [1](#MOESM1){ref-type="media"}). Hyperuricemia was defined, for both sexes, as serum urate ≥ 0.42 mmol/L (7 mg/dL).

All people with gout fulfilled the 1977 American Rheumatism Association gout classification criteria \[[@CR33]\]. Gout cases were recruited from New Zealand (979 Europeans, 912 Polynesians), Australia and Europe (720 Europeans). The 14,350 European controls (all self-reported as not having physician-diagnosed gout, not having kidney disease and not taking urate-lowering medication) were obtained from five sources: 452 individuals recruited from New Zealand, 6970 participants from the Atherosclerosis Risk in Communities (ARIC) study, 2689 participants from the Framingham Heart Study (FHS), 1492 participants from the Coronary Artery Risk Development in Young Adults (CARDIA) study, and 2747 participants from the Cardiovascular Health Study (CHS). Phenotypes from baseline exams were used for all studies with the exception of CARDIA, where phenotypes from exam six were used. The 696 Polynesian controls were recruited from New Zealand using the same exclusion criteria.

Ancestry for controls from ARIC, FHS, CARDIA and CHS was used as provided in these datasets. Ancestry for the NZ, Australian and European gout cases and the NZ controls was classified based on principal components computed from genome-wide SNP data. The NZ Polynesian sample set was divided into Eastern and Western Polynesian ancestral groups based on principal components from genome-wide genotype data \[[@CR34]\]. Eastern Polynesian comprised of Cook Island and NZ Māori (543 cases and 462 controls), while Western Polynesian comprised of Samoa, Tonga, Tuvalu, Niue and Tokelau (369 cases and 234 controls) \[[@CR35]\]. A separate NZ Māori sample set of 124 cases and 50 controls is included within the Eastern Polynesian sample set data presented above. These participants were recruited in collaboration with Ngāti Porou Hauora Charitable Trust from the Ngāti Porou *rohe* (tribal territory) located in the East Coast (Tairāwhiti) region of the North Island of Aotearoa New Zealand.

Genotyping {#Sec4}
----------

Three SNPs were examined: *rs2231142, rs10011796* (both *ABCG2*) and *rs11942223 (SLC2A9*). Genotypes for the NZ gout cases and controls, and for the European and Australian gout cases were determined using either (a) Taqman® assays (*rs2231142*: C_15854163_70; *rs10011796*: C_9510320_10; *rs11942223:* C_1216479_10; Applied Biosystems, Foster City, USA) on a Lightcycler® 480 machine (Roche Applied Science, IN, USA) or (b) Illumina Infinium CoreExome v24 bead chips processed at the University of Queensland (Centre for Clinical Genomics). Bead chip genotypes were auto-clustered using GenomeStudio v2011.1 software (Illumina, San Diego, USA). The Illumina GenomeStudio best practice guidelines and quality control protocols of Guo et al. \[[@CR36]\] were applied to these auto-clustered genotypes to ensure final genotype calls were of the highest possible quality. SNP *rs7442295* was identified as being in complete linkage disequilibrium with *rs11942223* in European and East Asian populations using LDLink \[[@CR37]\] and was used as a proxy on the bead chip for *rs11942223*. A total of 2940 samples were genotyped on both platforms for all 3 SNPs, with genotype concordance exceeding 99.8%.

Publicly available genotype data for the ARIC, FHS, CARDIA and CHS participants were used. These genotypes were generated by the Affymetrix 6.0 platform (ARIC and CARDIA datasets), the combined Affymetrix 50K and 500K platform (the FHS dataset), and the Illumina Human CNV370v1 platform (the CHS dataset). *Rs2231142* was genotyped on the Affymetrix 50K and 500K platforms and imputed using IMPUTE2 using the 1000 Genomes Phase I haplotype reference panel in the ARIC, CARDIA and CHS sample sets. Similarly, *rs10011796 (ABCG2)* and *rs11942223* (*SLC2A9*) were imputed in all four sample sets.

Statistical analysis {#Sec5}
--------------------

All analyses were performed using R v3.1.2 using RStudio 0.98. Deviation from Hardy-Weinberg equilibrium within each group (gout, HU controls and NU controls) was tested separately using the Haldane Exact test for Hardy-Weinberg equilibrium (*α* = 0.01) for each population and each SNP. Allelic association testing of *ABCG2 rs2231142* and *rs10011796*, and *SLC2A9 rs11942223* for comparison, with gout and HU was performed using logistic regression. We analysed gout vs. all controls, NU controls vs. HU controls, and gout vs. HU controls. The SNPs were also tested for association with serum urate concentration at recruitment in combined NU and HU controls using linear regression. Association of each of the three variants with self-reported number of gout flares over a 12-month period was examined using linear regression. Analyses were adjusted by age, sex (except male-only analyses) and principal components (PCs) 1 to 10 (Polynesian sample sets only). For association testing of gout in the presence of HU, analyses were additionally adjusted by highest recorded serum urate concentration. All Polynesian meta-analyses were performed in R using meta v4.8--2 \[[@CR38]\], and an inverse-variance fixed effect model unless otherwise stated.

Given the low linkage disequilibrium between *ABCG2 rs2231142* and *rs10011796* in European and East Asian populations (*r*^2^ = 0.087 and 0.12, respectively), genotypes were categorised as risk allele-positive or allele-negative for both SNPs, and association of *rs2231142-rs10011796* genotype combinations were tested for gout vs. all controls, and gout vs. HU controls using logistic regression. Non-additive interaction between the two SNPs in determining the risk of gout was also examined, including an interaction term between *rs2231142* and *rs10011796* in the multivariate-adjusted logistic regression model.

Results {#Sec6}
=======

Relevant demographic, anthropomorphic and biochemical characteristics of the various sample sets are presented in Additional file [1](#MOESM1){ref-type="media"}. At recruitment urate levels were higher in the HU group than in the gout group in both European (0.47 vs 0.41 mmol/L) and Polynesian (0.48 vs 0.43 mmol/L). In both European and Polynesian, there was a preponderance of males in the gout (84.7 and 82.5%, respectively) and HU sample sets (78.8 and 73.2% respectively) compared to NU (40.0 and 36.9%, respectively). Given this, along with evidence that *ABCG2 rs2231142* has a stronger effect on urate and gout in males than females \[[@CR13]\], male-only analyses were also done (Additional File [2](#MOESM2){ref-type="media"}), which yielded similar results.

The genotypes of all sample sets were in Hardy-Weinberg equilibrium (*P* \> 0.01). *ABCG2* SNPs *rs2231142* (Q141K) and *rs10011796* and, for comparison, the *SLC2A9* SNP *rs11942223* were tested for allelic association with (a) gout in the presence of HU (Table [1](#Tab1){ref-type="table"}; gout vs. HU), (b) gout per se (Table [1](#Tab1){ref-type="table"}; gout vs. all controls), (c) HU (Table [1](#Tab1){ref-type="table"}; HU vs. NU) and, (d) serum urate levels in controls (Table [2](#Tab2){ref-type="table"}). In European, the T allele of *rs2231142* (141K) was strongly associated with HU using NU controls (OR = 1.56, *P* = 1.7E^− 18^), and with gout when using HU controls (OR = 1.85, *P* = 3.8E^− 21^). In the Polynesian sample sets, there was no evidence for an effect of *rs2231142* in determining HU in Western Polynesian (OR = 1.52, *P* = 0.091) or Eastern Polynesian (OR = 1.41, *P* = 0.37) (Table [1](#Tab1){ref-type="table"}), with a Polynesian meta-analysis yielding OR~meta~ = 1.49, *P* = 0.057. We note that the Polynesian ORs were similar to that in Europeans, suggesting that the non-significance may be due to reduced power of the Polynesian sample set. However, *rs2231142* was associated by linear regression with serum urate levels in Polynesian (Table [2](#Tab2){ref-type="table"}; *β*~meta~ = 0.018 mmol/L, *P* = 0.014) with an effect size similar to European (*β* = 0.017 mmol/L, *P* = 8.9E^− 30^). In Polynesian, *rs2231142* was associated with the risk of gout compared to HU in Western Polynesian (OR = 1.77, *P* = 0.012), EP (OR = 2.02, *P* = 0.043), and the Polynesian meta-analysis (OR~meta~ = 1.85, *P* = 1.3E^− 03^) with effect sizes similar to that in Europeans (Table [1](#Tab1){ref-type="table"}). Table 1Association analysis of *rs2231142, rs10011796 (ABCG2)* and *rs11942223 (SLC2A9)* in European and NZ Polynesian sample setsSNPRaw NGenotype, *N* (%)^†^Effect allele, *N* (%)Gout vs. HU\*\^\
OR (95% CI), *P*Gout vs. All Controls\*\
OR (95% CI), *P*HU vs. NU\*\
OR, 95% CI, *Prs2231142*GGGTTTTEuropean gout16371006 (61.5)551 (33.7)80 (7.5)711 (21.7)1.81 (1.60--2.06), *3.0E−20*1.85 (1.63--2.11), *3.8E−21*2.42 (2.18--2.68), *1.9E−64*--European HU23781762 (74.1)577 (24.3)39 (1.6)655 (13.8)1.56 (1.41--1.72), *1.7E−18*European NU11,6049428 (81.2)2053 (17.7)123 (1.1)2299 (9.1)WP^\#^ gout36996 (26.0)189 (51.2)84 (22.8)357 (48.4)1.96 (1.30--3.00), *1.6E−03*1.77 (1.14--2.80), *0.012*^‡^2.36 (1.73--3.26), *1.1E−07*--WP HU8848 (54.6)29 (33.0)11 (12.5)51 (29.0)1.52 (0.94--2.50), *0.091*^‡^WP NU14684 (57.5)52 (35.6)10 (6.9)72 (24.7)--EP^\#^ gout543436 (80.3)106 (19.5)1 (0.2)108 (9.9)1.99 (1.05--4.05), *0.044*2.02 (1.05--4.16) *0.043*^‡^2.54 (1.66--3.97), *3.4E−05*--EP HU114101 (88.6)13 (11.4)0 (0.0)13 (5.7)1.41 (0.65--2.93), *0.37*^‡^EP NU348315 (90.5)32 (9.2)1 (0.3)34 (4.9)*rs10011796*CCCTTTTEuropean gout1580339 (21.5)764 (48.4)477 (30.2)1718 (54.4)1.39 (1.26--1.53), *2.0E−11*1.39 (1.26--1.53), *3.5E−11*1.55 (1.44--1.69), *1.3E−27*--European HU2422666 (27.5)1208 (49.9)548 (22.6)2304 (47.6)1.18 (1.10--1.26), *7.8E−07*European NU11,9273688 (30.9)5986 (50.2)2253 (18.9)10,492 (44.0)--WP gout36938 (10.3)163 (44.2)168 (45.5)499 (67.6)1.28 (0.86--1.91), *0.22*1.27 (0.83--1.94), *0.27*1.32 (0.99--1.77), *0.062*--WP HU8810 (11.4)43 (48.9)35 (39.8)113 (64.2)1.02 (0.66--1.60), *0.92*WP NU14621 (14.4)67 (45.9)58 (39.3)183 (62.7)EP gout54393 (17.2)259 (47.9)189 (34.9)637 (58.9)0.94 (0.68--1.29), *0.69*0.92 (0.66--1.27), *0.60*1.03 (0.83--1.27), *0.80*--EP HU11418 (15.8)51 (44.7)45 (39.5)141 (61.8)1.13 (0.81--1.57), *0.48*EP NU34867 (19.3)173 (49.7)108 (31.0)389 (55.9)*rs11942223*TTTCCCCEuropean gout15761168 (74.1)382 (24.2)26 (1.6)434 (13.8)0.72 (0.63--0.83), *2.9E−06*0.73 (0.63--0.83), *4.7E−06*0.55 (0.49--0.62), *1.4E−25*--European HU24221658 (68.5)701 (28.9)63 (2.6)827 (17.1)0.66 (0.61--0.73), *2.2E−21*European NU11,9277101 (59.5)4220 (35.4)606 (5.1)5432 (22.8)WP gout369351 (95.1)18 (4.9)0 (0.0)18 (2.4)0.53 (0.17--2.05), *0.31*0.51 (0.15--2.08), *0.31*0.61 (0.26--1.46), *0.26*--WP HU8884 (95.5)4 (4.6)0 (0.0)4 (2.3)0.83 (0.20--2.94), *0.78*WP NU146135 (92.5)11 (7.5)0 (0.0)11 (3.8)EP gout543501 (92.3)39 (7.2)3 (0.6)45 (4.1)1.04 (0.47--2.61), *0.92*1.24 (0.54--3.23), *0.64*1.06 (0.62--1.84), *0.84*--EP HU114105 (92.1)9 (7.9)0 (0.0)9 (3.9)1.26 (0.51--12.94), *0.60*EP NU348311 (89.4)37 (10.6)0 (0.0)37 (5.3)\*European sample set adjusted by age and sex. Polynesian sample sets additionally adjusted by PCs 1--10\^For Gout vs. HU analyses, the top data is before adjustment by highest recorded serum urate, and the bottom figure is after adjustment^†^All sample sets are in Hardy-Weinberg equilibrium (*P* \> 0.01)^‡^Polynesian meta-analysis of WP and EP Gout vs. HU, and of HU vs. NU yielded OR~meta~ = 1.85, *P* = 1.3E*−*03., and OR~meta~ = 1.49, *P* = 0.057, respectively\#*WP* Western Polynesian, *EP* Eastern PolynesianTable 2Association analysis of *rs2231142, rs10011796 (ABCG2)* and *rs11942223 (SLC2A9)* with serum urate at recruitment (mmol/L) in European and NZ Polynesian controlsSNP/alleleCombined sex\*Male only\**Nβ* mmol/L (SE)*PNβ* mmol/L (SE)*Prs2231142*/T European control13,9820.017 (1.5E*−*03)*8.9E−30*65140.020 (2.2E*−*03)*5.7E−20* WP control2340.019 (9.2E*−*03)*0.035*1340.027 (0.011)*0.017* EP control4620.015 (0.012)*0.19*1900.009 (0.023)*0.68Polynesian meta-analysis6960.018 (7.2E−03)0.0143240.024 (0.010)0.019rs10011796*/T European control14,3490.006 (9.2E*−*04)*1.7E−10*66820.006 (4.7E*−*03)*1.5E−06* WP control2340.006 (8.5E*−*03)*0.51*1340.006 (0.011)*0.62* EP control4620.005 (5.0E*−*03)*0.33*1900.000 (8.1E*−*03)*0.99Polynesian meta-analysis6960.005 (4.3E−03)0.943240.002 (6.6E−03)0.77rs11942223*/C European control14,349*−* 0.024 (1.1E*−*03)*8.4E−106*6681*−* 0.017 (1.6E*−*03)*8.1E−27* WP control234*−* 0.021 (0.023)*0.38*134*−* 0.038 (0.038)*0.32* EP control462*−* 0.008 (0.012)*0.53*1900.052 (0.022)*0.022Polynesian meta-analysis\^696− 0.011 (0.011)0.633240.012 (0.044)0.78*\*European sample set adjusted by age and sex (combined sex only). Polynesian sample sets additionally adjusted by PCs 1--10\^As the test for heterogeneity between Western Polynesian (WP) and Eastern Polynesian (EP) was significant (p = 0.043), a random effects model was used

The strength of association of *ABCG2 rs2231142* with gout in the presence of HU in European was significantly different to *SLC2A9 rs11942223* (OR~risk\ allele~ = 1.85 for *rs2231142* compared to OR~risk\ allele~ = 1.37 for *rs11942223*, *P*~Het~ = 2.1E^− 03^). In contrast, the effect sizes on HU in European were not significantly different (OR~risk\ allele~ = 1.56 for *rs2231142* compared to OR~risk\ allele~ = 1.52 for *rs11942223*, *P*~Het~ = 0.64). In the Polynesian sample set, the minor allele of *rs11942223* was uncommon (\< 5% in most groups) with no nominally significant (*P* \< 0.05) associations detected in the three gout and HU analyses (Table [1](#Tab1){ref-type="table"}). To test the possibility that inclusion of both sexes in the analysis was influencing, the results a male-only analysis was done, which yielded similar data (Additional file [2](#MOESM2){ref-type="media"}).

*ABCG2 rs10011796* displayed a similar pattern of association in Europeans as *rs2231142*, albeit with a weaker effect size (OR = 1.39, *P* = 3.5E^− 11^ for gout vs. HU, and OR = 1.18, *P* = 7.8E^− 07^ for HU vs. NU). However, *rs10011796* was not significantly associated in any of the three comparisons (gout vs. HU, gout vs. all controls, HU vs. NU) in any of the Polynesian sample sets (all *P* \> 0.06) (Table [1](#Tab1){ref-type="table"}).

The three SNPs of interest were tested for association with gout flare frequency in each sample set (Table [3](#Tab3){ref-type="table"}). The *ABCG2 rs2231142* T allele was associated with an additional 2.54 and 2.16 self-reported flares per year in the WP and meta-analysed Polynesian sample sets (Table [3](#Tab3){ref-type="table"}; *P* = 8.9E^− 03^ and *P*~meta~ = 2.5E^− 03^, respectively) but not in European (*P* = 0.97). Neither *rs10011796* nor *rs11942223* was associated with flare frequency in any sample set. Table 3Association analysis of *rs2231142, rs10011796 (ABCG2)* and *rs11942223 (SLC2A9)* gout risk alleles with the number of self-reported gout flares in the previous year by gout patientsSNP/risk allele*Nβ* (SE)\**Prs2231142*/T European gout921− 0.019 (0.479)*0.97* Western Polynesian gout3592.54 (0.965)*8.9E−03* Eastern Polynesian gout4811.69 (1.061)*0.11Polynesian meta-analysis8402.16 (0.714)2.5E−03rs10011796*/T European gout9200.29 (0.396)*0.47* Western Polynesian gout3590.46 (0.982)*0.64* Eastern Polynesian gout481− 1.02 (0.638)*0.11Polynesian meta-analysis840- 0.58 (0.535)0.28rs11942223*/T European gout924− 0.11 (0.596)*0.85* Western Polynesian gout3591.80 (3.122)*0.56* Eastern Polynesian gout4812.53 (1.440)*0.080Polynesian meta-analysis8402.40 (1.308)0.067*\*European sample set adjusted by age and sex. Polynesian sample sets additionally adjusted by PCs 1--10

Non-additive interaction between *rs2231142* and *rs10011796* in determining the risk of gout was examined for gout vs. all controls, and gout vs. HU (Table [4](#Tab4){ref-type="table"}). The interaction of *rs2231142* and *rs10011796* was significant in European gout vs. all controls (*P* = 7.9E^− 03^) but did not reach significance in the gout vs. HU analysis (*P* = 0.062). There was no evidence for significant interaction in any of the Polynesian sample sets. Stratification by genotype groups (Table [5](#Tab5){ref-type="table"}) revealed that the interaction was driven by a non-additive contribution to the risk of gout (gout vs. all controls) when the *rs2231142* risk-positive genotype group (GT,TT) was combined with the *rs10011796* risk-negative genotype (CC). The ORs for this genotype combination were higher than the ORs for risk-positive genotypes at both SNPs (European OR = 3.78 vs. 3.37; Western Polynesian OR = 4.81 vs. 4.40; Eastern Polynesian OR = 2.88 vs. 2.45). The gout vs. HU controls analysis yielded similar findings in Europeans as using all controls, but with reduced ORs (Table [5](#Tab5){ref-type="table"}). However, there was a strikingly high risk for gout in the *rs2231142* risk positive and *rs10011796* risk negative category in Western Polynesian (OR = 21.5, *P* = 8.6 × 10^− 3^). Table 4Interaction terms between *rs2231142* and *rs10011796* in determining risk of gout in European and NZ Polynesian sample setsSample SetGout vs. All Controls\*Gout vs. HU\**N*OR~Interaction~ (95% CI)*PN*OR~Interaction~ (95% CI)*P*European15,5590.61 (0.43--0.88)*7.9E-03*39560.65 (0.41--1.02)*0.062*Western Polynesian6030.62 (0.17--2.11)*0.45*4570.10 (0.01--1.09)*0.059*Eastern Polynesian10030.89 (0.25--2.92)*0.85*6551.48 (0.18--8.32)*0.67Polynesian meta-analysis16060.75 (0.31--1.78)0.5111120.54 (0.13--2.32)0.41*\*European sample set adjusted by age and sex. Polynesian sample sets additionally adjusted by PCs 1--10Table 5Risk of gout in *rs2231142-rs10011796* genotype combinations classified by absence/presence of gout risk allelesGenotypeGout vs. All Controls\*Gout vs. HU Controls\*Sample Set*rs2231142\^rs10011796\^*Controls\
*N* (%)Gout\
*N* (%)OR (95% CI)*P*HU Controls\
*N* (%)Gout\
*N* (%)OR (95% CI)*P*European13,981157823781578GGCC3996 (28.6)280 (17.7)1.00--601 (25.3)280 (17.7)1.00*--*GG**CT, TT**7193 (51.4)687 (43.5)1.46 (1.26--1.71)*9.2E*--*07*1161 (48.8)687 (43.5)1.33 (1.11--1.59)*2.1E*--*03***GT, TT**CC247 (1.8)59 (3.7)3.78 (2.67--5.28)*1.8E*--*14*53 (2.2)59 (3.7)2.60 (1.70--3.98)*9.9E*--*06***GT, TTCT, TT**2545 (18.2)552 (35.0)3.37 (2.87--3.98)*2.8E*--*48*563 (23.7)552 (35.0)2.24 (1.85--2.73)*5.8E*--*16*WP23436988369GGCC22 (9.4)14 (3.8)1.00--9 (10.2)14 (3.8)1.00GG**CT, TT**110 (47.0)82 (22.2)1.47 (0.63--3.54)*0.38*39 (44.3)82 (22.2)2.39 (0.81--6.98)*0.11***GT, TT**CC9 (3.8)24 (6.5)4.81 (1.53--16.06)*8.5E*--*03*1 (1.1)24 (6.5)21.52 (3.05--449.83)*8.6E*--*03***GT, TTCT, TT**93 (39.7)249 (67.5)4.40 (1.92--10.33)*5.1E*--*04*39 (44.3)249 (67.5)5.26 (1.84--14.74)*1.6E*--*03*EP462541114541GGCC77 (16.7)72 (13.3)1.00--16 (14.0)72 (13.3)1.00--GG**CT, TT**339 (73.4)362 (66.9)0.96 (0.63--1.46)*0.85*85 (74.6)362 (66.9)0.83 (0.42--1.57)*0.58***GT, TT**CC8 (1.7)21 (3.9)2.88 (0.98--9.25)*0.064*2 (1.8)21 (3.9)1.44 (0.31--10.58)*0.67***GT, TTCT, TT**38 (8.2)86 (15.9)2.45 (1.36--4.47)*3.2E*--*03*11 (9.6)86 (15.9)1.78 (0.72--4.52)*0.22*\*European sample set adjusted by age and sex. Polynesian sample sets additionally adjusted by PCs 1--10\^The T allele (presence highlighted in bold) is the gout risk allele in European for both SNPs

Discussion {#Sec7}
==========

We report association of the *ABCG2 rs2231142* 141K (T) allele with gout in the presence of HU in European, Eastern and Western Polynesian sample sets. In all sample sets, the effect size was substantial (OR = 1.77--2.02) (Table [1](#Tab1){ref-type="table"}). These results are consistent with a role for *ABCG2* in the progression from HU to gout. This conclusion is supported by the association of 141K with flare frequency in Polynesians (*P*~meta~ = 2.5E^− 03^) (Table [3](#Tab3){ref-type="table"}). For *rs10011796*, there was evidence for association with gout in the presence of HU and with HU in Europeans only. Stratification of genotypes by presence or absence of gout-risk allele in the HU vs gout analysis provides evidence for an epistatic interaction between *rs2231142* and *rs10011796* most notably in Western Polynesian (Table [5](#Tab5){ref-type="table"}). The addition of the 141K risk allele to the non-risk *rs10011796* CC-genotype increased risk of gout for these individuals non-additively from 1.0 to 21.5 in the gout vs. HU analysis. We did observe an effect also for *SLC2A9 rs11942223* in the gout vs HU comparison for Europeans (OR = 1.37 for risk allele); however, this was notably weaker than that for *ABCG2 rs2231142* (OR = 1.85; *P*~Het~ = 0.0023).

It is increasingly clear that there is heterogeneity in the frequency of the pathogenic 141K variant between the ancestrally defined Western Polynesian (Samoa, Tonga, Niue, Tokelau) and Eastern Polynesian (New Zealand Māori, Cook Island Māori) populations of New Zealand. Although the T allele has a similar gout risk effect size, it is fivefold more prevalent in Western Polynesian (Table [1](#Tab1){ref-type="table"}) and will, therefore, have a greater impact on this population. It is also a known risk factor for tophus in the presence of gout in Western Polynesian (OR = 1.66) but not in Eastern Polynesian (OR = 0.91) \[[@CR39]\]. The striking interaction of the risk T allele of *rs2231142* with *rs10011796* in promoting gout in the presence of HU is observed in Western Polynesian but not Eastern Polynesian sample sets (Table [5](#Tab5){ref-type="table"}). Finally, we found association of the 141K allele with flare frequency in Western Polynesian but not Eastern Polynesian (Table [3](#Tab3){ref-type="table"}). Collectively, at *ABCG2* at least, these findings emphasise the need to carefully account for ancestry in studies investigating the genetic causes of gout in the Polynesian populations of New Zealand.

There are parallels between ABCG2 141K and the important cystic fibrosis-causing gene variant, ΔF508 in CFTR, also an ABC transporter. Both variants cause instability in the nucleotide binding domain of their respective proteins and can be corrected by small molecules \[[@CR20], [@CR23]\]. Accumulation of aggresomes is a feature of both ABCG2 141K and cystic fibrosis \[[@CR40]\], indicative of impaired and/or inadequate protein degradation. Dysfunctional autophagosome clearance in cystic fibrosis leads to a hyper-inflammatory state in which there is increased reactive oxygen species and impaired autophagy. This activates the NLRP3 inflammasome \[[@CR41]\]. In addition, there is accumulation of p62, a protein that regulates aggresome formation by delivering ubiquitinated proteins for degradation by autophagy, resulting in increased IL-1β production by promoting cleavage of pro-caspase-1 to caspase-1 \[[@CR42]\]. The IL-1β produced further increases p62 levels \[[@CR40]\] resulting in defective autophagy in cystic fibrosis via accumulation of misfolded proteins in aggresomes. Reducing p62 levels allows localization of ΔF508 CFTR to the cell surface where it can function \[[@CR40]\]. In gout, MSU crystals impair proteasomal degradation causing increased expression of p62 \[[@CR42]\], and it is likely that proteasomal degradation is impaired in the presence of the 141K variant as evidenced by the formation of aggresomes \[[@CR23]\]. ABCG2 promotes autophagy in cancer cell lines exposed to stressors such as nutrient deprivation \[[@CR43]\], although the ability of the 141K allele to impair autophagy is not yet established. It is possible that defective autophagy resulting from the 141K variant could lead to increased IL-1β signalling, since autophagy normally allows for negative feedback regulation of IL-1β production via degradation of the NLRP3 inflammasome \[[@CR44]\]. Autophagy is necessary for formation of neutrophil extracellular traps that attenuate the inflammatory response to MSU crystals \[[@CR45]\]. Future studies that investigate and compare IL-1β production in response to MSU and autophagy in cells with the different 141Q and 141K alleles would be illuminating.

The molecular mechanism driving the non-additive interaction between *ABCG2* SNPs *rs2231142* and *rs10011796* is unclear. Given that *rs10011796* is a noncoding intronic variant outside any known Encode regulatory motif features ([www.encodeproject.org](http://www.encodeproject.org)), it is likely that *rs10011796* is in linkage disequilibrium with the causal variant, rather than the causal variant itself, although other intronic variants in *ABCG2* have been associated with ABCG2 expression \[[@CR46], [@CR47]\]. The majority of common phenotype associations identified by GWAS are expression quantitative trait loci \[[@CR48]\], influencing gene expression and transcript stability, and these variants can therefore modify the penetrance of coding variants \[[@CR49]\]. Thus, it is reasonable to hypothesise that *rs10011796* marks an effect that influences gene expression. This is consistent with the presence of an expression QTL (regulatory) effect independent of *rs2231142* in the *ABCG2* urate GWAS signal \[[@CR47]\]. The *rs10011796* C-allele (that associates with reduced serum urate and risk of gout) does associate with reduced *ABCG2* and increased *PPM1K-DT* (a long non-coding RNA 100 kb downstream of *ABCG2*) expression ([www.gtex.org](http://www.gtex.org)). How *rs10011796* (or more likely a variant in linkage disequilibrium) could synergise with *rs2231142* to amplify the risk of gout is unclear. However, it has previously been reported that a urate-associated variant at the *MAF* locus influences the expression of MAF via a long non-coding RNA \[[@CR50]\]. It is possible that in Western Polynesian people with HU, the combination of the 141K risk allele with the *rs10011796* CC-genotype has an epistatic effect where an altered amount of 141K is internalised, disrupting important stoichiometric relationships and promoting gouty inflammation. Finally, it is interesting to note that local epistatic interactions have also been reported at *SLC2A9* in the control of urate levels \[[@CR51]\].

In addition to the common Q141K variant, there are numerous other uncommon and rare missense variants in ABCG2, mostly detected by resequencing *ABCG2* exons in people with gout. These variants tend, as does 141K, to reduce the urate transport ability of ABCG2 \[[@CR52]\]; they associate with gout \[[@CR52], [@CR53]\] and, including 141K, associate with an earlier age-of-onset of gout \[[@CR52], [@CR54]\]. The effect size on gout is similar to that of 141K---increasing risk two to threefold \[[@CR53]\]. It is possible that the rare and uncommon variants also contribute to the progression from HU to gout; however, testing this hypothesis will require very large datasets. Of significance for the study of the pathogenesis of gout is the possibility that genetic variation in other genes contribute both to HU and the progression from HU to gout. In our data, there was a suggestion that *SLC2A9* could be one such gene.

Conclusion {#Sec8}
==========

We provide genetic epidemiological evidence supporting a role for ABCG2 141K in the progression from HU to gout, additional to its role in promoting HU. The variant may promote a hyper-inflammatory state akin to that observed with the cystic fibrosis gene, *CFTR* ΔF508*,* featuring defective autophagy, formation of aggresomes, and activation of the NLPR3 inflammasome. An *ABCG2* genotype combination (*rs2231142-rs10011796*) confers especially high risk for gout in Polynesian people with hyperuricaemia.
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